Millennium Management LLC Has $191,000 Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Millennium Management LLC lessened its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 59.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,310 shares of the company’s stock after selling 42,173 shares during the period. Millennium Management LLC’s holdings in Recursion Pharmaceuticals were worth $191,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in RXRX. Novo Holdings A S acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $68,375,000. Vanguard Group Inc. increased its stake in Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock valued at $229,908,000 after buying an additional 9,737,196 shares during the last quarter. Norges Bank purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $23,429,000. Laurion Capital Management LP purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $16,611,000. Finally, Nan Fung Group Holdings Ltd purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $4,493,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

RXRX has been the subject of several analyst reports. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Morgan Stanley reduced their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Finally, Needham & Company LLC reduced their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.60.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $5.17 on Friday. The firm’s fifty day moving average price is $4.87 and its 200-day moving average price is $6.33. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market cap of $2.10 billion, a P/E ratio of -3.38 and a beta of 0.84. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The business had revenue of $14.75 million during the quarter, compared to analysts’ expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.39) EPS. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.